Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On February22, 2017, Esperion Therapeutics,Inc. issued a press
release announcing its financial results for the three months and
year-ended December31, 2016 (the Press Release). A copy of the
Press Release is furnished herewith as Exhibit99.1.
The information set forth under Item 2.02 and in Exhibit99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as expressly set
forth by specific reference in such filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release dated February22, 2017. |
About Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors. Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information
Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session down -0.58 at 24.42 with 1,260,646 shares trading hands.
